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Abstract
Objective
To investigate whether fibromyalgia induces axonal damage in the optic nerve that can be
detected using optical coherence tomography (OCT), as the retinal nerve fiber layer (RNFL)
is atrophied in patients with fibromyalgia compared with controls.
Methods
Fibromyalgia patients (n = 116) and age-matched healthy controls (n = 144) were included
in this observational and prospective cohort study. All subjects underwent visual acuity
measurement and structural analysis of the RNFL using two OCT devices (Cirrus and Spec-
tralis). Fibromyalgia patients were evaluated according to Giesecke’s fibromyalgia sub-
groups, the Fibromyalgia Impact Questionnaire (FIQ), and the European Quality of Life-5
Dimensions (EQ5D) scale. We compared the differences between fibromyalgia patients
and controls, and analyzed the correlations between OCT measurements, disease dura-
tion, fibromyalgia subgroups, severity, and quality of life. The impact on quality of life in fibro-
myalgia subgroups and in patients with different disease severity was also analyzed.
Results
A significant decrease in the RNFL was detected in fibromyalgia patients compared with
controls using the two OCT devices: Cirrus OCT ganglion cell layer analysis registered a
significant decrease in the minimum thickness of the inner plexiform layer (74.99±16.63 vs
79.36±3.38 μm, respectively; p = 0.023), nasal inferior, temporal inferior and temporal supe-
rior sectors (p = 0.040; 0.011 and 0.046 respectively). The Glaucoma application of the
Spectralis OCT revealed thinning in the nasal, temporal inferior and temporal superior sec-
tors (p = 0.009, 0.006, and 0.002 respectively) of fibromyalgia patients and the Axonal appli-
cation in all sectors, except the nasal superior and temporal sectors. The odds ratio (OR) to
estimate the size effect of FM in RNFL thickness was 1.39. RNFL atrophy was detected in
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patients with FIQ scores <60 (patients in early disease stages) compared with controls in
the temporal inferior sector (78.74±17.75 vs 81.65±3.61; p = 0.020) and the temporal supe-
rior sector (78.20±14.50 vs 80.74±3.88; p = 0.039) with Cirrus OCT; in the temporal inferior
sector (145.85±24.32 vs 150.18±19.71; p = 0.012) and temporal superior sector (131.54
±20.53 vs 138.13±16.67; p = 0.002) with the Glaucoma application of the Spectralis OCT;
and in all sectors, except the average, nasal superior, and temporal sectors, and parame-
ters with the Axonal application of the Spectralis OCT. Temporal inferior RNFL thickness
was significantly reduced in patients with severe fibromyalgia (FIQ60) compared with
patients with mild fibromyalgia (FIQ<60; 145.85±24.32 vs 138.99±18.09 μm, respectively;
145.43±13.21 vs 139.85±13.09 μm, p = 0.032 with the Glaucoma application and p = 0.021
with the Axonal application). The subgroup with biologic fibromyalgia exhibited significant
thinning in the temporal inferior and superior sectors (115.17±20.82 μm and 117.05
±24.19 μm, respectively) compared with the depressive (130.83±22.97 μm and 127.71
±26.10 μm, respectively) and atypical (128.60±26.54 μm and 125.55±23.65 μm, respec-
tively) subgroups (p = 0.005 and 0.001 respectively).
Conclusions
Fibromyalgia causes subclinical axonal damage in the RNFL that can be detected using
innocuous and non-invasive OCT, even in the early disease stages. The impact on
the RNFL in the temporal sectors is greater in patients with biologic fibromyalgia, suggest-
ing the presence of neurodegenerative processes in this subgroup of patients with
fibromyalgia.
Introduction
Fibromyalgia (FM) is a central nervous system disorder and a type of central sensitivity syn-
drome [1]. The neurophysiologic basis of pain processing was recently evaluated with greater
resolution using functional neuroimaging. Mountz et al., using single-photon emission com-
puted tomography, observed bilateral hypoperfusion in the thalamus and caudate nucleus in
women with fibromyalgia [1]. Gracely et al., using functional magnetic resonance imaging
(MRI), revealed a significant relative increase in signal intensity in multiple pain-related brain
regions in patients with FM after challenging both FM patients and controls with the same
painful stimulus [2]. Based on a perfusion MRI study, Foerster et al. reported baseline changes
in brain perfusion in patients with FM, especially in the thalami [3,4].
Garcia-Campayo et al. suggested that neuroimaging findings could be used to identify sub-
groups of FM patients, which would allow for personalized patient treatment [5]. These func-
tional imaging techniques are expensive, however, and not readily available in a typical clinical
practice. Currently, there are no easy and quick objective examinations for diagnosing FM or
for assessing the severity of the disorder [6].
Visual loss is a main cause of disability in patients with neurodegenerative disease, and axo-
nal loss in the retinal nerve fiber layer (RNFL) correlates with the extent of functional disability
in patients with neurodegenerative disease, such as multiple sclerosis [7–10], Parkinson disease
[9,11,12], and Alzheimer disease [13,14]. The RNFL comprises retinal ganglion cell axons that
send information from the retina to the lateral geniculate nucleus. RNFL axons within the eye
have no myelin sheath. In addition to being the main retinal component near the optic nerve
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(90% of retinal thickness), ganglion cells and their axons are also present in the macula (30%-
35%) and can be quantified using noninvasive, rapid, objective, and reproducible ocular imag-
ing technologies, such as optical coherence tomography (OCT), which is commonly used to
evaluate the RNFL [13,15,16].
The aim of this study was to evaluate whether FM causes RNFL thinning and which sub-
types or phases of this pathology exhibit high axonal damage in the optic nerve. We used two
commonly available OCT devices to test which protocols more accurately detect whether FM
causes axonal damage in the RNFL. Possible correlations of RNFL measurements in FM
patients with disease duration, FM subgroup, functional ability, and quality of life were also
analyzed.
Materials and Methods
This is a prospective cohort study aiming to compare patients with FM (n = 119) against age-
and sex-matched controls (n = 144).
Based on our previous studies, 86 subjects were needed to be able to detect significant differ-
ences in the RNFL thickness, assuming an alpha error of 5% and a beta error of 10%. A stan-
dard sample size equation was used to calculate the number of subjects required. To further
increase the power of the study, we included 119 FM patients and 144 controls.
Patients were recruited from the primary care research group study population of FM
patients in Zaragoza, Spain. This research group periodically evaluates all subjects with FM
diagnosis or clinical suspects among healthy individuals of Zaragoza, which has a population
of 850.000.
All participants signed their written informed consent to participate in this study. The writ-
ten informed consents for patients and controls and the study protocol were approved by the
Ethic Committee of Clinic Research in Aragon (CEICA) and by the Ethic Committee of Miguel
Servet University Hospital, in Zaragoza, Spain. This study was conducted in accordance with
the guidelines established by the principles of the Declaration of Helsinki.
The inclusion criteria were: confirmed FM diagnosis according to the 1990 American Col-
lege of Rheumatology criteria for FM [17]; best corrected visual acuity0.1 using a Snellen
chart to allow the patients to complete the protocol; and intraocular pressure less than 21
mmHg to exclude other processes, such as open angle chronic glaucoma, related to RNFL thin-
ning [18]. The exclusion criteria were: history of refractive errors (more than 5 diopters of
spherical equivalent refraction or 3 diopters of astigmatism); concomitant ocular disease (such
as glaucoma or retinal pathology); systemic pathologies that could impair the visual system;
ocular trauma, laser therapy; and pathology affecting the optic nerve, cornea, retina, or lens
(such as glaucoma, optic neuritis, keratoconus, macular degeneration, and cataract). Controls
presented with no evidence of any disease. All procedures were performed in adherence to the
tenets of the Declaration of Helsinki, and the local ethics committee approved the experimental
protocol. Informed consent to participate in the study was provided by all subjects.
The FM patients were evaluated by a psychiatrist specializing in FM (blind to the ophthal-
mology evaluation), who registered measurements of disease duration since diagnosis; evalua-
tion of FM severity using the Fibromyalgia Impact Questionnaire (FIQ); evaluation of activities
of daily living and impact on quality of life using the Euro Quality of Life 5D (EQ-5D) scale.
All subjects were evaluated by two neuro-ophthalmologists (blind to the psychiatrist evalua-
tion), who examined the anterior segment, assessed the best-corrected visual acuity based on
the Snellen scale, and performed a visual field test, three different OCT protocols, and a fundo-
scopic exam. Each eye was considered independently and we randomly analyzed only one eye
of each subject unless only one of the eyes met the exclusion criteria. We assessed the visual
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field using a Humphrey Field Analyzer (Carl-Zeiss Meditec, Dublin, CA). Mean deviation
(dB), defect pattern, and pattern standard deviation were measured using the Swedish Interac-
tive Threshold Algorithm Standard strategy (program 30–2).
OCT evaluation
Peripapillary RNFL thickness measurements were obtained in all subjects using the Cirrus and
Spectralis OCT devices. The OCT devices were used in random order to prevent fatigue bias.
The same experienced operator performed all of the scans and was blinded to the results of the
psychiatric and other ophthalmologic tests. A time delay was inserted between scan acquisi-
tions and subject position and focus was randomly disrupted for adjustment of the alignment
parameters at the beginning of each scan. The OCT output was not manually corrected. We
used an internal fixation target to provide the highest level of reproducibility [19], and only
analyzed images with a quality a score of>7 for the Cirrus OCT and>25 for Spectralis OCT.
Three patients were excluded because poor fixation prevented us from acquiring a centered
scan, and therefore only 116 patients were included in the statistical analysis. We also excluded
10 images due to artifacts, missing parts, or apparently distorted anatomy. Ten eyes were
rescanned (six with the Cirrus OCT and four using the Spectralis OCT) to obtain good-quality
and centered images [20].
The Cirrus Macular Cube 200 x 200 protocol was performed using the Cirrus OCT. Each
scan was analyzed using the ganglion cell layer analysis application to measure the mean and
minimum inner plexiform, the fovea, and the nasal and temporal sectors. With the Spectralis
OCT, we used two different RNFL applications in each of the subjects: the classic Glaucoma
application and the Axonal application (created specifically to evaluate neurologic diseases that
impact the RNFL). The images were acquired using TruTrack eye-tracking technology. Both
RNFL applications generate a thickness map indicating mean overall thickness, mean thickness
for each of the superior, inferior, nasal and temporal quadrants, and mean thickness of the
nasal superior, nasal, nasal inferior, temporal inferior, temporal, and temporal superior sectors
(Fig 1). RNFL defects were identified by comparing each patient’s measurements with those of
the normative database provided with each instrument. The Axonal application utilizes fovea-
to-disc technology to orient the anatomy correctly and to minimize variability due to differ-
ences in patient head orientation. In addition, the Axonal system places the temporal region of
the scan in the center of the viewing window to enhance analysis of papillomacular bundle axo-
nal loss, which occurs in neurodegenerative disease. The RNFL thickness graph displays the
scan results in the quadrants, and provides two additional neuro-ophthalmologic parameters:
papillomacular bundle thickness and nasal/temporal (N/T) ratio.
Assessment of the Fibromyalgia syndrome
Disease duration since diagnosis was recorded (in months) and all patients were classified fol-
lowing FM subgrouping at the Miguel Servet Hospital Fibromyalgia Unit, based on the pres-
sure-pain thresholds and psychologic factors described by Giesecke et al [21]. Despite the
existence of several FM subgroup classifications, Giesecke’s classification method is considered
highly reliable by FM researchers and specialists because it is based on both psychologic and
biologic measures. The Giesecke classification includes three subgroups: Subgroup 1 (atypical):
low tenderness, moderate depression/anxiety, moderate catastrophizing, and moderate control
over pain; Subgroup 2 (depressive): high tenderness, high depression/anxiety, high catastro-
phizing, and low control over pain; and Subgroup 3 (biologic): high tenderness, low depres-
sion/anxiety, low catastrophizing, and high control over pain. The questionnaires and
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examinations used to classify FM patients into these subgroups are described in Giesecke et al.
[21].
We used the FIQ because it has reliable test-retest characteristics, credible construct validity,
and good sensitivity for demonstrating therapeutic effects in patients with FM [22]. Patients in
the present study completed the FIQ and were assigned a score of 0 through 100. The higher
the score, the greater the disease impact. We used the validated Spanish version of the FIQ
[23].
We assessed the symptoms of patients with FM and the impact on activities of daily living
using the Euro-quality of life questionnaire (EQ-5D). It is critical to assess health-related qual-
ity of life outcomes in FM patients because of the multitude of symptoms, which include
chronic pain, fatigue, weakness, hyperalgesia, secondary depression, and allodynia. These
symptoms can substantially impair the patients’ ability to work and disrupt their quality of life
by interfering with social and family functioning. The EQ-5D comprises five questions with
Fig 1. Representation and interpretation of the report from the Axonal application of the Spectralis optical coherence tomography in a control (left
side) and in a patient with fibromyalgia and retina nerve fiber layer thinning (right side).
doi:10.1371/journal.pone.0161574.g001
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three response categories involving the following dimensions: mobility, self-care, usual activi-
ties, pain, and anxiety/ depression. The EQ-5D results are expressed as the percentage of sub-
jects with moderate or major problems [24]. We used the validated Spanish version of the EQ-
5D [25].
Statistical analysis
Data were stored in a custom database (File Maker Pro, version 8.5) The Statistical Package for
the Social Sciences (SPSS 20.0, SPSS Inc., Chicago, IL) was used for the statistical analyses.
Sample distribution was assessed using the Kolmogorov-Smirnov test, and therefore mean,
standard deviation and standard error of the mean were used in the descriptive analysis, and
parametric tests were used for comparison.
The OCT and ophthalmologic parameters were normally distributed and differences
between controls and FM patients were assessed using unpaired Student’s t-test (two sided)
and analysis of variance (ANOVA). Bonferroni’s correction for multiple comparisons was used
to adjust for multiple comparisons (p-value with Bonferroni´s correction was 0.012). The odds
ratio (OR) was calculated to estimate the size effect of FM in RNFL thinning.
The FM population was divided in two subgroups: 68 patients with severe FM (FIQ60)
and 48 patients with mild FM (FIQ<60). We compared both subgroups with controls to evalu-
ate the presence of RNFL atrophy in even the early stages of FM disease. We also evaluted the
differences among the biologic FM, depressive FM, and atypical FM subgroups. Correlations
between OCT measurements, disease duration, severity (measured by FIQ), and impact on
quality of life (by EQ-5D) were calculated using Pearson’s correlation coefficient. We analyzed
which OCT measurements showed better sensitivity for detecting disease severity (FIQ) and
impact on quality of life (EQ05D) in FM patients, using a multivariate logistical regression
analysis.
Results
We evaluated a total of 116 patients with FM and 144 age- and sex-matched controls. Mean
age was 52.13±8.34 years in the FM group and 51.11±8.98 years in the control group. Age, sex,
and intraocular pressure did not differ significantly between FM and control groups.
Table 1 shows the epidemiologic and disease characteristics. FM duration ranged from 6
months to 24 years with a median of 7.9 years since diagnosis. The FM phenotype distribution
was: biologic FM, 26 patients (22.4%); depressive FM, 34 patients (29.3); atypical FM, 56
patients (48.3%). The FIQ scores ranged from 18.39 to 97.61 (mean 62.15). The EQ-5D scores
ranged from 5 to 95 (mean 45.05).
Best corrected visual acuity, mean deviation, and standard deviation of the visual field did
not differ significantly between FM patients and controls (Table 1) (S1 Table. Minimal datset)
RNFL thickness comparisons between FM and controls
Based on findings from both OCT devices, FM patients had significantly reduced RNFL thick-
ness (Table 2, Fig 2). The Cirrus OCT ganglion cell layer analysis revealed significant differ-
ences in the minimum inner plexiform, the nasal inferior, temporal inferior, and temporal
superior sector thicknesses in FM patients (see Table 2).
The odds ratio (OR) was calculated to estimate the size effect of FM in RNFL thinning using
the following formula: OR = (ad) / (bc). The coefficient “a” indicates FM patients who pres-
ent with a thickness reduction in at least one temporal sector or the papillomacular buddle of
the Axonal application of the Spectralis OCT (using the normative database of this device).
The coefficient “b” indicates healthy subjects with a thickness decrease in those parameters.
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The coefficients “c” and “d” indicate FM patients and healthy controls without a thickness
decrease in those parameters, respectively. The OR obtained was 1.39.
The two applications used with the Spectralis OCT (the classic Glaucoma application RNFL
protocol and the Axonal application RNFL-N protocol) revealed significant differences in the
nasal and temporal sectors in FM patients. The Axonal application also revealed that FM
patients had a significant thinning of the papillomacular bundle and a significant increase in
the N/T (nasal/temporal) index (Table 2; Fig 1). Although other sectors showed clear tenden-
cies toward RNFL thinning (Fig 2), the differences were not statistically significant (Table 2).
Subgroup analysis
Based on the FIQ, the FM population was divided in two subgroups: 68 patients with severe
FM (FIQ60) and 48 patients with mild FM (FIQ<60). Both subgroups exhibited statistically
significant differences when compared with controls in Temporal Inferior sector using Cirrus
Ganglion cell layer analysis, in Temporal Superior and Temporal Inferior sectors using Glau-
coma RNFL application of Spectralis OCT and in all measurements provided by Axonal
RNFL-N application of Spectralis OCT (except Average thickness, Nasal Superior and Tempo-
ral sectors) (Table 3). The RNFL temporal inferior sector thickness obtained with both Spectra-
lis OCT applications was significantly reduced in patients with severe FM (FIQ60) compared
with patients with mild FM (FIQ<60; p = 0.032 with the Glaucoma application and 0.021 with
Axonal application). Based on Bonferroni´s correction, the differences between severe and
mild FM were not statistically significant. Based on the Axonal application, RNFL temporal
superior thickness in patients with severe FM was significantly reduced compared with patients
with an FIQ score lower than 60 (p = 0.018).
The FM population was also divided in three subgroups depending on Giesecke’s classifica-
tion of FM using the same instruments: biologic FM (26 patients), depressive FM (34 patients),
and atypical FM (56 patients). Statistical differences were detected between patients with bio-
logic FM and the other two groups in the thicknesses of the temporal inferior and temporal
superior sectors using the Spectralis OCT Axonal application: the biologic FM subgroup had
significant thinning in the temporal inferior and superior sectors (115.17±20.82 μm and 117.05
±24.19 μm, respectively) compared with the depressive FM (130.83±22.97 μm and 127.71
Table 1. Epidemiologic and disease characteristics of 116 patients with fibromyalgia syndrome and 144 controls included in the study, and statis-
tical significance of the comparisons between the groups (P).
Patients with Fibromyalgia syndrome (n = 116) Controls (n = 144) P*
Age (years): mean (range) 52.1 (33–69) 51.1 (32–70) 0.393
Men:Women (% women) 4:112 (98.2%) 6:138 (95.83%) 0.103
Disease duration (years): mean (SD) 7.88 (4.23) - -
FIQ: mean (SD) 62.1 (18.72) - -
EQ-5D: mean (SD) 45.0 (18.84) - -
Intraocular pressure (SD) 14.1 (1.21) 14.0 (1.32) 0.540
BCVA (ETDRS scale): mean (SD) -0.01 (0.46) -0.02 (0.35) 0.607
MD Visual Field [mean (SD)] 1.9 (3.14) -0.4 (2.22) 0.212
PSD Visual Field (dB) [mean (SD)] 1.2 (1.74) 1.34 (1.04) 0.324
Abbreviations: EQ-5D, FIQ, Fibromyalgia Impact Questionnaire; European Quality of Life-5 Dimensions; BCVA, best corrected visual acuity; ETDRS, Early
Treatment Diabetic Retinopathy Study; dB, decibels; MD, mean deviation of visual field; PSD, pattern standard deviation of visual field;.
*Significant difference (P<0.05) between normal subjects and Fibromyalgia syndrome patients for each population were calculated using unpaired Student’s
t-test (two sided).
doi:10.1371/journal.pone.0161574.t001
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±26.10 μm, respectively) and atypical FM (128.60±26.54 μm and 125.55±23.65 μm, respec-
tively) subgroups (ANOVA; p = 0.005 for the temporal superior sector and p = 0.001 for the
temporal inferior sector) (Table 4).
Correlation analysis and logistic regression between OCT and disease
parameters
Measurements of the RNFL by the Cirrus OCT and by the Spectralis OCT’s Glaucoma applica-
tion were significantly positively correlated (r = 0.789, p<0.001 between the mean inner
plexiform layer thickness of the Cirrus OCT and mean RNFL thickness of the Glaucoma appli-
cation). Similarly, RNFL measurements by the Cirrus OCT and the Spectralis OCT’s Axonal
application were significantly positively correlated (r = 0.767; p<0.001, between the mean
inner plexiform of the Cirrus, and the RNFL mean thickness of the Axonal application). Corre-
lation between the two Spectralis applications was good (r = 0.881; p<0.001, RNFL mean
Table 2. Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence
tomography devices in patients with Fibromyalgia syndrome and controls, and statistical significance.
Fibromyalgia patients
(n:116)
Controls (n:144) P
Mean SEM Mean SEM
Cirrus Ganglion cell layer analysis Average Inner Plexiform 80.6 1.02 82.5 0.85 0.207
Minimum Inner Plexiform 75.0 0.99 79.4 0.72 0.023
Fovea 257.4 1.67 258.3 1.41 0.728
Superior sector 81.3 1.19 83.5 0.78 0.166
Nasal Superior sector 83.4 1.17 84.6 1.03 0.535
Nasal Inferior sector 80.8 1.54 83.4 1.06 0.040
Inferior sector 79.3 1.22 81.2 0.68 0.300
Temporal Inferior sector 78.6 1.39 81.6 0.98 0.011*
Temporal Superior sector 77.2 0.97 80.7 1.01 0.046
Spectralis RNFL(Glaucoma application) Average 97.6 1.02 99.9 0.97 0.114
Nasal Superior sector 104.3 2.73 107.2 2.72 0.376
Nasal sector 73.0 1.96 78.5 1.17 0.009*
Nasal Inferior sector 111.7 2.98 116.1 2.73 0.277
Temporal Inferior sector 142.1 2.24 150.2 1.81 0.006*
Temporal sector 68.8 1.59 70.1 0.96 0.498
Temporal Superior sector 129.5 2.28 138.1 1.53 0.002*
Spectralis RNFL-N(Axonal application) Average 97.5 1.12 100.0 1.01 0.047
Nasal Superior sector 104.1 1.32 105.4 1.21 0.123
Nasal sector 65.4 1.21 71.3 1.34 0.006*
Nasal Inferior sector 103.6 1.60 108.9 1.55 0.002*
Temporal Inferior sector 142.1 0.83 149.0 0.79 <0.001*
Temporal sector 70.4 0.95 72.4 0.88 0.187
Temporal Superior sector 143.9 1.32 150.0 1.21 <0.001*
Papillomacular buddle 53.6 0.80 57.5 0.77 <0.001*
Nasal/Temporal index 0.89 0.01 1.01 0.01 0.012*
Thickness measurements are in microns (μm). Abbreviations: SEM, standard error of the mean; RNFL, retinal nerve fiber layer. P: Student’s t-test between
normal and Fibromyalgia disease groups.
Numbers in bold indicate significant difference (P<0.05)
* indicate significant difference using Bonferroni correction for multiple comparisons for each application of optical coherence tomography device (p<0.012).
doi:10.1371/journal.pone.0161574.t002
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Fig 2. Bar charts representing optical coherence tomography (OCT) measurements in eyes from 116
fibromyalgia patients and 144 controls. A- Retinal nerve fiber layer measurements using the ganglion cell
layer analysis of Cirrus OCT device. B- Retinal nerve fiber layer measurements using the Glaucoma analytic
Axonal Damage in Fibromyalgia
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thickness). Mean RNFL thickness values obtained with the three applications differed signifi-
cantly (ANOVA, p = 0.016). The RNFL thicknesses provided by the three applications did not
significantly correlate with disease duration or with FIQ and EQ-5D scores. Based on stepwise
logistic regression analysis (using step-forward selection), the OCT parameters did not predict
disease severity in FM patients (low FIQ score) or impaired quality of life (low EQ-5D score).
application of the Spectralis OCT device. C- Retinal nerve fiber layer measurements using the Nsite RNFL
Axonal application of the Spectralis OCT device.
doi:10.1371/journal.pone.0161574.g002
Table 3. Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence
tomography devices in patients with early and advantage stages of Fibromyalgia syndrome and statistical significance with controls.
Fibromyalgia patients with FIQ<60
(n:48)
Fibromyalgia patients with
FIQ60 (n:68)
Mean SEM P* Mean SEM P**
Cirrus Ganglion cell layer analysis Average Inner Plexiform 81.0 1.11 0.433 80.3 0.98 0.329
Minimum Inner Plexiform 76.0 0.78 0.102 74.1 1.23 0.018
Fovea 258.2 1.64 0.435 256.7 1.71 0.691
Superior sector 81.8 1.05 0.237 81.1 1.34 0.430
Nasal Superior sector 83.6 1.16 0.349 83.2 1.18 0.667
Nasal Inferior sector 82.0 1.44 0.056 81.2 1.50 0.031
Inferior sector 78.9 1.15 0.543 79.1 1.30 0.211
Temporal Inferior sector 78.7 1.46 0.020 78.3 1.32 0.038
Temporal Superior sector 78.2 1.02 0.039 77.8 0.95 0.067
Spectralis RNFL (Glaucoma application) Average 98.1 0.91 0.609 97.8 1.13 0.078
Nasal Superior sector 106.8 2.57 0.441 103.0 3.01 0.601
Nasal sector 75.9 1.88 0.098 69.6 2.10 0.022
Nasal Inferior sector 113.3 3.13 0.654 109.5 2.67 0.265
Temporal Inferior sector 145.8 2.23 0.012* 139.0 2.26 0.003*
Temporal sector 67.0 1.47 0.342 68.3 1.78 0.561
Temporal Superior sector 131.5 2.29 0.002* 127.3 2.26 0.009*
Spectralis RNFL-N (Axonal application) Average 98.7 1.10 0.078 97.8 1.08 0.038
Nasal Superior sector 104.3 1.43 0.345 104.9 1.21 0.098
Nasal sector 67.3 1.26 0.004* 64.9 1.16 0.007*
Nasal Inferior sector 105.8 1.55 0.003* 102.6 1.66 0.002*
Temporal Inferior sector 145.4 0.80 0.001* 139.8 0.87 <0.001*
Temporal sector 71.9 0.80 0.453 71.0 1.34 0.089
Temporal Superior sector 146.4 1.23 <0.001* 141.9 1.42 <0.001*
Papillomacular buddle 55.9 0.83 0.003* 53.6 0.78 <0.001*
Nasal/Temporal index 0.98 0.01 0.010* 0.98 0.01 0.008*
Thickness measurements are in microns (μm). Abbreviations: FIQ, Fibromyalgia Impact Questionnaire; SEM, standard error of the mean; RNFL, retinal
nerve fiber layer.
P*: Student’s t-test between controls and Fibromyalgia patients with smaller disease severity (FIQ<60).
P**: Student’s t-test between controls and Fibromyalgia patients with higher disease severity (FIQ60). Numbers in bold indicate significant difference
(P<0.05).
Numbers in bold indicate a significant difference (P<0.05)
* indicates a significant difference using the Bonferroni correction for multiple comparisons for each application of the optical coherence tomography device
(p<0.012).
doi:10.1371/journal.pone.0161574.t003
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Although we detected a correlation between OCT parameters, FIQ, and EQ-5D scores, this
association did not demonstrate prognostic utility in this study.
Discussion
The main finding in the present study evaluating RNFL parameters in patients with FM was
the presence of axonal damage in the optic nerve of FM patients, even in early stages of the dis-
ease. Our results revealed that even patients with mild FM (FIQ<60) exhibited subclinical
RNFL atrophy in the temporal sectors.
Currently, FM lacks a specific and definitive diagnostic test. The results of the present study
provide a new option to facilitate the diagnosis of FM. The ability to evaluate the optic nerve as
an indicator of the disease is an important advance, and this examination can be easily imple-
mented in clinical practice, because OCT tests are noninvasive, fast, and comfortable for
patients, as well as inexpensive.
Previous studies described neurobiologic and structural brain abnormalities in FM [26,27].
Clauw described FM as a "central sensitization syndrome" caused by neurobiologic abnormalities
Table 4. Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence
tomography devices in patients with biologic fibromyalgia (26 patients), depressive fibromyalgia (34 patients), and atypical fibromyalgia (56
patients).
Biologic
fibromyalgia
Depressive
fibromyalgia
Atypical
fibromyalgia
P
Mean SEM Mean SEM Mean SEM
Cirrus Ganglion cell layer analysis Average Inner Plexiform 80.2 0.88 77.5 1.21 81.7 0.95 0.452
Fovea 258.4 0.97 254.9 1.10 258.1 1.00 0.391
Inferior sector 78.5 1.55 75.5 1.78 81.0 1.67 0.552
Minimum Inner Plexiform 73.9 1.03 72.7 0.98 75.4 1.28 0.418
Nasal Inferior sector 81.3 1.22 75.9 1.19 82.6 1.02 0.691
Nasal Superior sector 82.7 1.50 79.5 1.59 85.2 1.57 0.379
Superior sector 80.5 1.31 79.7 1.33 81.7 0.99 0.672
Temporal Inferior sector 79.8 1.41 77.3 1.35 82.0 1.27 0.590
Temporal Superior sector 78.8 0.94 76.4 0.97 78.2 1.01 0.872
Spectralis RNFL(Glaucoma application) Average 96.2 1.23 94.1 1.11 98.6 0.92 0.315
Nasal Superior sector 103.3 2.77 103.4 2.80 105.2 2.65 0.470
Nasal sector 82.8 2.08 75.5 1.77 77.1 2.11 0.102
Nasal Inferior sector 115.2 3.16 104.0 2.65 109.6 3.03 0.247
Temporal Inferior sector 142.1 2.31 130.8 2.03 146.3 2.21 0.111
Temporal sector 63.9 1.46 67.9 1.55 69.8 1.34 0.199
Temporal Superior sector 117.0 1.80 127.7 1.96 133.7 2.09 0.367
Spectralis RNFL-N(Axonal application) Average 97.0 1.23 97.8 1.13 99.1 1.01 0.890
Nasal Superior sector 102.1 1.32 104.7 1.31 103.8 1.34 0.498
Nasal sector 66.7 1.01 67.9 1.33 68.1 1.28 0.550
Nasal Inferior sector 105.2 1.60 106.0 1.70 106.2 1.50 0.669
Temporal Inferior sector 115.2 0.80 130.8 0.84 128.6 0.85 0.005
Temporal sector 70.8 1.15 72.4 1.04 72.4 0.88 0.209
Temporal Superior sector 117.0 1.27 127.7 1.35 125.5 1.31 0.001
Papillomacular buddle 53.5 0.78 56.0 0.83 54.6 0.78 0.255
Nasal/Temporal index 1.02 0.01 0.98 0.01 0.98 0.01 0.098
Thickness measurements are in microns (μm). Abbreviations: SEM, standard error of the mean; RNFL, retinal nerve fiber layer.
doi:10.1371/journal.pone.0161574.t004
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that produce neuropsychologic symptoms [27]. Our findings support this emerging theory and
contribute new knowledge regarding the etiology of this little-known disease because we
observed axonal damage in the optic nerve, which suggests that neurodegeneration contributes
to the pathology of FM.
The ophthalmologic tests described in this study allow for the eye to be utilized as a “win-
dow” to the central nervous system, specifically to directly observe the axons in the optic nerve.
Previous studies demonstrated that eye assessment can provide useful information for early
diagnosis of some neurodegenerative diseases, such as Parkinson disease, multiple sclerosis,
and Alzheimer disease [8,9,13,16]. The optic nerve is a cranial nerve considered part of the cen-
tral nervous system because it derives from the diencephalon during embryonic development.
Once the fibers exit the eye globe, they are covered with myelin produced by oligodendrocytes,
which are myelinating cells in the central nervous system. Peripheral neuropathies, such as
Guillain-Barré syndrome, do not affect the optic nerve.
The first portion of the optic nerve is one millimeter long and locates within the eyeball.
This portion of the optic nerve lacks myelin or meningeal layers, and thus axonal damage can
be evaluated in this segment using OCT and high resolution photographs. OCT is suggested to
be more accurate than MRI for quantifying axonal damage in multiple sclerosis patients [28–
30]. RNFL thickness is well-correlated with MRI measurements of the brain, such as the brain
volumes and the parenchymal fraction, and mean RNFL thickness is strongly associated with
normalized brain volume [29,31].
The fibers of the temporal quadrant follow the papillomacular bundle, so the temporal
RNFL quadrant is most often affected in early neurodegenerative diseases [32]. Our results in
FM patients are consistent with these findings: we have found that papillomacular bundle
thickness decreased in patients with FM with the temporal sector being the most vulnerable
(the N/T index was higher in the FM group because the temporal quadrant was affected more
by the RNFL thinning than the other sectors).
We also detected differences between FM subgroups. Patients with biologic FM (low depres-
sion/anxiety/catastrophizing but high tenderness) had a significant decrease in the temporal
inferior and temporal superior sectors compared with patients suffering from depressive or
atypical FM, suggesting the presence of neurodegenerative processes in the biologic FM sub-
group. These findings are reasonable because these patients have a high pain level but not the
associated psychiatric disorders (depression/anxiety) that explain this pain, so a lesion of the
tissues would be the most sensible explanation. Studies with a larger sample size will likely
detect greater differences between the three FM subgroups.
OCT evaluation is noninvasive, inexpensive, fast, and comfortable for the patient. OCT
does not require pupil dilation, and thus does not impact the patient’s vision. While patients
may occasionally be temporarily blinded following the test, this lasts only 1 or 2 minutes. Obvi-
ously, FM patients should be diagnosed and followed-up by a rheumatologist, but ophthalmo-
logic tests are new, noninvasive, and cost-effective tools than can be used to facilitate the
diagnosis of FM and may reduce the expenses associated with diagnosis of this disease. Evalua-
tion of the RNFL in FM patients will enhance our knowledge of the disease etiology.
The two applications used with the Spectralis OCT (the classic Glaucoma application RNFL
protocol and the Axonal application RNFL-N protocol) revealed significant differences in the
nasal and temporal sectors in FM patients. The Axonal application also revealed that FM
patients had a significant thinning of the papillomacular bundle and a significant increase in
the N/T (nasal/temporal) index (Table 2; Fig 1). Although other sectors showed clear tenden-
cies toward RNFL thinning (Fig 2), the differences were not statistically significant (Table 2).
This study has some limitations. First, although we checked that both groups (patients and
controls) had no differences in refractive error, we did not evaluate axial length, which may
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interfere with the results. Second, our logistic regression analysis found that OCT parameters
did not predict disease severity in FM patients, although we did detect correlations. Studies
with a larger sample size or longitudinal studies may find a predictive association between
RNFL thinning and FM severity or changes in the quality of life. Third, in this study, we used
no internal or external validation techniques to corroborate the results. Finally, we found that
the RNFL temporal inferior sector thickness obtained with both Spectralis OCT applications
was significantly reduced in patients with severe FM (FIQ60), but these results were not sta-
tistically significant when Bonferroni´s correction was applied, so this difference is uncertain.
Again, studies with a larger sample size might shed more light on this point.
Longer-term studies are required to evaluate the clinical application of RNFL measurements
in FM patients as a diagnostic tool, to follow disease progression, to identify patients with worse
prognosis or at higher risk for loss of quality of life, and to measure treatment effectiveness.
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